WO2022235140A1 - 단일사슬항체조각 및 페리틴의 융합단백질을 포함하는 나노입자 및 이의 용도 - Google Patents
단일사슬항체조각 및 페리틴의 융합단백질을 포함하는 나노입자 및 이의 용도 Download PDFInfo
- Publication number
- WO2022235140A1 WO2022235140A1 PCT/KR2022/006597 KR2022006597W WO2022235140A1 WO 2022235140 A1 WO2022235140 A1 WO 2022235140A1 KR 2022006597 W KR2022006597 W KR 2022006597W WO 2022235140 A1 WO2022235140 A1 WO 2022235140A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ferritin
- fusion protein
- protein
- nanoparticles
- hrid
- Prior art date
Links
- 238000008416 Ferritin Methods 0.000 title claims abstract description 130
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 116
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 116
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 114
- 239000012634 fragment Substances 0.000 title claims abstract description 58
- 108050000784 Ferritin Proteins 0.000 title claims abstract description 55
- 102000008857 Ferritin Human genes 0.000 title claims abstract description 53
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 108010092041 Lysine-tRNA Ligase Proteins 0.000 claims abstract description 11
- 102000017737 Lysine-tRNA Ligase Human genes 0.000 claims abstract 4
- 108090000623 proteins and genes Proteins 0.000 claims description 60
- 102000004169 proteins and genes Human genes 0.000 claims description 60
- 210000004027 cell Anatomy 0.000 claims description 58
- 229960000397 bevacizumab Drugs 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 29
- 239000013604 expression vector Substances 0.000 claims description 27
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 26
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 26
- 229960000575 trastuzumab Drugs 0.000 claims description 23
- 239000000178 monomer Substances 0.000 claims description 22
- 229960002087 pertuzumab Drugs 0.000 claims description 19
- 238000001338 self-assembly Methods 0.000 claims description 15
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 241000238631 Hexapoda Species 0.000 claims description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 210000004102 animal cell Anatomy 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 241000588722 Escherichia Species 0.000 claims description 3
- 241000589516 Pseudomonas Species 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000013598 vector Substances 0.000 abstract description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 13
- 230000004927 fusion Effects 0.000 abstract description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
- 230000027455 binding Effects 0.000 description 29
- 241000588724 Escherichia coli Species 0.000 description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 27
- 239000000203 mixture Substances 0.000 description 19
- 102000039446 nucleic acids Human genes 0.000 description 19
- 108020004707 nucleic acids Proteins 0.000 description 19
- 150000007523 nucleic acids Chemical class 0.000 description 19
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 16
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 16
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 16
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 101000818390 Homo sapiens Ferritin light chain Proteins 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 15
- 150000001413 amino acids Chemical group 0.000 description 13
- 229960000723 ampicillin Drugs 0.000 description 13
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 239000011534 wash buffer Substances 0.000 description 13
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 101001002987 Homo sapiens Ferritin heavy chain Proteins 0.000 description 11
- 102000054087 human FTH1 Human genes 0.000 description 11
- 229920001213 Polysorbate 20 Polymers 0.000 description 10
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 10
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 10
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 10
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 9
- 238000001042 affinity chromatography Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 8
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 210000001525 retina Anatomy 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 102100035529 Lysine-tRNA ligase Human genes 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 150000002460 imidazoles Chemical class 0.000 description 6
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000011426 transformation method Methods 0.000 description 6
- 239000013638 trimer Substances 0.000 description 6
- 238000002604 ultrasonography Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000004570 RNA-binding Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 102220614566 Calmodulin-3_K19A_mutation Human genes 0.000 description 4
- 102220518416 Casein kinase I isoform gamma-2_K23A_mutation Human genes 0.000 description 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 4
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- 108020004566 Transfer RNA Proteins 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 229940120638 avastin Drugs 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 230000012846 protein folding Effects 0.000 description 4
- 238000001742 protein purification Methods 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010006519 Molecular Chaperones Proteins 0.000 description 3
- 229920002472 Starch Chemical class 0.000 description 3
- 239000001913 cellulose Chemical class 0.000 description 3
- 229920002678 cellulose Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- ABFYEILPZWAIBN-UHFFFAOYSA-N 3-(iminomethylideneamino)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.CN(C)CCCN=C=N ABFYEILPZWAIBN-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102220482776 BRCA1-A complex subunit RAP80_K31A_mutation Human genes 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102220614559 Calmodulin-3_K30A_mutation Human genes 0.000 description 2
- 102220614553 Calmodulin-3_R24A_mutation Human genes 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000658867 Homo sapiens Lysine-tRNA ligase Proteins 0.000 description 2
- 102220643082 Inhibitor of nuclear factor kappa-B kinase subunit epsilon_K38A_mutation Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 206010063916 Metastatic gastric cancer Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 102220500923 Telomerase reverse transcriptase_K35D_mutation Human genes 0.000 description 2
- 102220484178 Thioredoxin domain-containing protein 8_K27A_mutation Human genes 0.000 description 2
- 102220484308 Thioredoxin domain-containing protein 8_K40A_mutation Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000003161 choroid Anatomy 0.000 description 2
- 238000002983 circular dichroism Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- -1 for example Proteins 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000013532 laser treatment Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000012557 regeneration buffer Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 1
- IFKQPMZRDQZSHI-GHCJXIJMSA-N Ala-Ile-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O IFKQPMZRDQZSHI-GHCJXIJMSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- RRGPUNYIPJXJBU-GUBZILKMSA-N Arg-Asp-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O RRGPUNYIPJXJBU-GUBZILKMSA-N 0.000 description 1
- HPKSHFSEXICTLI-CIUDSAMLSA-N Arg-Glu-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HPKSHFSEXICTLI-CIUDSAMLSA-N 0.000 description 1
- UHFUZWSZQKMDSX-DCAQKATOSA-N Arg-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UHFUZWSZQKMDSX-DCAQKATOSA-N 0.000 description 1
- DTBPLQNKYCYUOM-JYJNAYRXSA-N Arg-Met-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 DTBPLQNKYCYUOM-JYJNAYRXSA-N 0.000 description 1
- QJWLLRZTJFPCHA-STECZYCISA-N Arg-Tyr-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O QJWLLRZTJFPCHA-STECZYCISA-N 0.000 description 1
- NVWJMQNYLYWVNQ-BYULHYEWSA-N Asn-Ile-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O NVWJMQNYLYWVNQ-BYULHYEWSA-N 0.000 description 1
- GHODABZPVZMWCE-FXQIFTODSA-N Asp-Glu-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O GHODABZPVZMWCE-FXQIFTODSA-N 0.000 description 1
- DTNUIAJCPRMNBT-WHFBIAKZSA-N Asp-Gly-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O DTNUIAJCPRMNBT-WHFBIAKZSA-N 0.000 description 1
- JNNVNVRBYUJYGS-CIUDSAMLSA-N Asp-Leu-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O JNNVNVRBYUJYGS-CIUDSAMLSA-N 0.000 description 1
- NAAAPCLFJPURAM-HJGDQZAQSA-N Asp-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O NAAAPCLFJPURAM-HJGDQZAQSA-N 0.000 description 1
- YUELDQUPTAYEGM-XIRDDKMYSA-N Asp-Trp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)O)N YUELDQUPTAYEGM-XIRDDKMYSA-N 0.000 description 1
- XMKXONRMGJXCJV-LAEOZQHASA-N Asp-Val-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XMKXONRMGJXCJV-LAEOZQHASA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001200922 Gagata Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- MGJMFSBEMSNYJL-AVGNSLFASA-N Gln-Asn-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MGJMFSBEMSNYJL-AVGNSLFASA-N 0.000 description 1
- XEYMBRRKIFYQMF-GUBZILKMSA-N Gln-Asp-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O XEYMBRRKIFYQMF-GUBZILKMSA-N 0.000 description 1
- TWTWUBHEWQPMQW-ZPFDUUQYSA-N Gln-Ile-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O TWTWUBHEWQPMQW-ZPFDUUQYSA-N 0.000 description 1
- QXQDADBVIBLBHN-FHWLQOOXSA-N Gln-Tyr-Phe Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QXQDADBVIBLBHN-FHWLQOOXSA-N 0.000 description 1
- VTTSANCGJWLPNC-ZPFDUUQYSA-N Glu-Arg-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VTTSANCGJWLPNC-ZPFDUUQYSA-N 0.000 description 1
- WATXSTJXNBOHKD-LAEOZQHASA-N Glu-Asp-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O WATXSTJXNBOHKD-LAEOZQHASA-N 0.000 description 1
- SJPMNHCEWPTRBR-BQBZGAKWSA-N Glu-Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SJPMNHCEWPTRBR-BQBZGAKWSA-N 0.000 description 1
- KASDBWKLWJKTLJ-GUBZILKMSA-N Glu-Glu-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O KASDBWKLWJKTLJ-GUBZILKMSA-N 0.000 description 1
- LRPXYSGPOBVBEH-IUCAKERBSA-N Glu-Gly-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O LRPXYSGPOBVBEH-IUCAKERBSA-N 0.000 description 1
- SOEPMWQCTJITPZ-SRVKXCTJSA-N Glu-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N SOEPMWQCTJITPZ-SRVKXCTJSA-N 0.000 description 1
- QCMVGXDELYMZET-GLLZPBPUSA-N Glu-Thr-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QCMVGXDELYMZET-GLLZPBPUSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- NZAFOTBEULLEQB-WDSKDSINSA-N Gly-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN NZAFOTBEULLEQB-WDSKDSINSA-N 0.000 description 1
- HHSOPSCKAZKQHQ-PEXQALLHSA-N Gly-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)CN HHSOPSCKAZKQHQ-PEXQALLHSA-N 0.000 description 1
- LLZXNUUIBOALNY-QWRGUYRKSA-N Gly-Leu-Lys Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN LLZXNUUIBOALNY-QWRGUYRKSA-N 0.000 description 1
- MHXKHKWHPNETGG-QWRGUYRKSA-N Gly-Lys-Leu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O MHXKHKWHPNETGG-QWRGUYRKSA-N 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- KZTLOHBDLMIFSH-XVYDVKMFSA-N His-Ala-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O KZTLOHBDLMIFSH-XVYDVKMFSA-N 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- LKACSKJPTFSBHR-MNXVOIDGSA-N Ile-Gln-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N LKACSKJPTFSBHR-MNXVOIDGSA-N 0.000 description 1
- UAQSZXGJGLHMNV-XEGUGMAKSA-N Ile-Gly-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N UAQSZXGJGLHMNV-XEGUGMAKSA-N 0.000 description 1
- PKGGWLOLRLOPGK-XUXIUFHCSA-N Ile-Leu-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PKGGWLOLRLOPGK-XUXIUFHCSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- UCOCBWDBHCUPQP-DCAQKATOSA-N Leu-Arg-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O UCOCBWDBHCUPQP-DCAQKATOSA-N 0.000 description 1
- DLCOFDAHNMMQPP-SRVKXCTJSA-N Leu-Asp-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DLCOFDAHNMMQPP-SRVKXCTJSA-N 0.000 description 1
- VQPPIMUZCZCOIL-GUBZILKMSA-N Leu-Gln-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O VQPPIMUZCZCOIL-GUBZILKMSA-N 0.000 description 1
- QVFGXCVIXXBFHO-AVGNSLFASA-N Leu-Glu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O QVFGXCVIXXBFHO-AVGNSLFASA-N 0.000 description 1
- PBGDOSARRIJMEV-DLOVCJGASA-N Leu-His-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(O)=O PBGDOSARRIJMEV-DLOVCJGASA-N 0.000 description 1
- DRWMRVFCKKXHCH-BZSNNMDCSA-N Leu-Phe-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=CC=C1 DRWMRVFCKKXHCH-BZSNNMDCSA-N 0.000 description 1
- FACUGMGEFUEBTI-SRVKXCTJSA-N Lys-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCCCN FACUGMGEFUEBTI-SRVKXCTJSA-N 0.000 description 1
- JBRWKVANRYPCAF-XIRDDKMYSA-N Lys-Asn-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N JBRWKVANRYPCAF-XIRDDKMYSA-N 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- MYAPQOBHGWJZOM-UWVGGRQHSA-N Met-Gly-Leu Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C MYAPQOBHGWJZOM-UWVGGRQHSA-N 0.000 description 1
- QGRJTULYDZUBAY-ZPFDUUQYSA-N Met-Ile-Glu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O QGRJTULYDZUBAY-ZPFDUUQYSA-N 0.000 description 1
- AXHNAGAYRGCDLG-UWVGGRQHSA-N Met-Lys-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O AXHNAGAYRGCDLG-UWVGGRQHSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000808007 Mus musculus Vascular endothelial growth factor A Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 101150008132 NDE1 gene Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 101100293738 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ro-11 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- AMBLXEMWFARNNQ-DCAQKATOSA-N Pro-Asn-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]1CCCN1 AMBLXEMWFARNNQ-DCAQKATOSA-N 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- BKZYBLLIBOBOOW-GHCJXIJMSA-N Ser-Ile-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O BKZYBLLIBOBOOW-GHCJXIJMSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- GFJXBLSZOFWHAW-JYJNAYRXSA-N Tyr-His-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O GFJXBLSZOFWHAW-JYJNAYRXSA-N 0.000 description 1
- MVFQLSPDMMFCMW-KKUMJFAQSA-N Tyr-Leu-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O MVFQLSPDMMFCMW-KKUMJFAQSA-N 0.000 description 1
- RVGVIWNHABGIFH-IHRRRGAJSA-N Tyr-Val-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O RVGVIWNHABGIFH-IHRRRGAJSA-N 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- WJVLTYSHNXRCLT-NHCYSSNCSA-N Val-His-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(=O)O)C(=O)O)N WJVLTYSHNXRCLT-NHCYSSNCSA-N 0.000 description 1
- BZMIYHIJVVJPCK-QSFUFRPTSA-N Val-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N BZMIYHIJVVJPCK-QSFUFRPTSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 108010027375 bacterioferritin Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003619 fibrillary effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 108010048994 glycyl-tyrosyl-alanine Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008202 granule composition Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108010085203 methionylmethionine Proteins 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000008107 starch Chemical class 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 108010015666 tryptophyl-leucyl-glutamic acid Proteins 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 108010000998 wheylin-2 peptide Proteins 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/85—Fusion polypeptide containing an RNA binding domain
Definitions
- the present invention relates to an N-terminal domain RID (RNA-interaction domain) of ferritin, a single-chain antibody fragment linked to the N-terminus of ferritin, and a human-derived lysyl tRNA synthetase coupled to the N-terminus of the single-chain antibody fragment. It relates to a fusion protein comprising a fusion protein, self-assembled nanoparticles of the fusion protein, an expression vector containing a nucleotide encoding the fusion protein, and novel uses thereof.
- the fusion protein and nanoparticles of the present invention have the advantage of greatly enhancing water solubility by using RID, and by varying the origin of single-chain antibody fragments, a pharmaceutical composition for treating a desired disease can be prepared.
- Viruses are largely divided into two types: enveloped viruses and non-enveloped viruses.
- the viral epidermis consists only of capsid proteins, and thus self-assembly into VLPs is possible only with capsid proteins.
- enveloped viruses essentially require a membrane component to form a virus. Therefore, for self-assembly into virus-like particles (VLPs), membrane components are required in addition to surface antigens. That is, in the envelope-virus-like particle (VLP) self-assembly process, not only the folding of the monomeric antigen protein but also its lipid membrane is essential.
- the lipid membrane is structurally non-uniform and difficult to characterize, so the formation of VLPs could only be generated in higher cells (animal cells, insect cells, human-derived cells, yeast, etc.). Therefore, there is a need for a method for commonly constructing various antigenic proteins by recombination and expression of a self-assembling protein as a scaffold instead of a membrane component.
- Ferritin is present in most biological species and has the characteristic of self-assembling to form nanoparticles.
- viral nanoparticles were formed in eukaryotic cells (insects and animal cells) using human-derived ferritin or Helicobacter pylori ferritin (L. He, N. de Val et al.: Presenting nativelike trimeric HIV).
- -1 antigens with self-assembling nanoparticles Nat Commun, 7, 12041 (2016) doi:10.1038/ncomms12041, H. M. Yassine et al.: Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nature medicine, 21(9), 1065-1070 (2015)).
- the eukaryotic cell production system has problems such as high cost, low productivity, and difficult mass production process.
- the present inventors intend to solve the above problem and use the nanoparticles prepared through this as a disease-specific therapeutic agent.
- An object of the present invention to solve the problems of the prior art is to produce a single-chain variable fragment, which is difficult to express in water-soluble in E. coli, in a water-soluble manner, and to self-assemble to form a stable nanoparticle.
- Another object of the present invention is to provide a method for preparing a water-soluble fusion protein and nanoparticles using the recombinant expression vector and host cell.
- Another object of the present invention is to provide a pharmaceutical composition for the prevention, improvement or treatment of diseases comprising the nanoparticles prepared by the above manufacturing method.
- the present inventors used RID (RNA-interaction domain) among human-derived lysyl tRNA synthetase at the N-terminus of a single-chain variable fragment as a novel fusion partner, and at the N-terminus of ferritin, the single A fusion protein to which a chain antibody fragment is bound, a nanoparticle in which the fusion protein is self-assembled, and an expression vector thereof were prepared, and using this, an insoluble single-chain variable fragment, which was difficult to produce in the prior art, can be refolded without refolding. It was produced with water solubility.
- RID RNA-interaction domain
- ferritin (ferritin) protein a single-chain variable fragment binding to the N-terminus of the ferritin; and an N-terminal domain (hLysRS Nterminal appended RNA interacting domain; hRID) separated from a human-derived lysyl tRNA synthetase, bound to the N-terminus of the single-chain antibody fragment, the nanoparticles are provided.
- a recombinant expression vector comprising a polynucleotide encoding is provided.
- the type of the single-chain antibody fragment of the present invention is not limited, but most preferably from any one antibody selected from the group consisting of Trastuzumab, Bevacizumab and Pertuzumab. it is derived
- the hRID may be represented by the amino acid sequence of SEQ ID NO: 1
- the ferritin protein may be represented by the amino acid sequence of SEQ ID NO: 4.
- the vector may include a linker between the polynucleotide encoding the single-chain antibody fragment (scFv) and the polynucleotide encoding the ferritin.
- the linker may be represented by an amino acid sequence represented by any one of the nucleotide sequences of SEQ ID NOs: 8 to 10.
- the present invention also provides a host cell transformed with the expression vector.
- the host cell may be used without limitation any host cell readily available to those skilled in the art to which the present invention belongs, but preferably, the host cell is Escherichia bacterium, Bacillus genus bacteria, It may be selected from the group consisting of Pseudomonas genus bacteria, lactic acid bacteria, yeast, animal cells and insect cells, and most preferably Escherichia coli.
- ferritin (ferritin) protein a single-chain variable fragment bound to the N-terminus of the ferritin protein; and an N-terminal domain (hLysRS N-terminal appended RNA interacting domain; hRID) isolated from human lysyl tRNA synthetase, bound to the N-terminus of the single-chain antibody fragment; expression comprising a polynucleotide encoding preparing a vector; (b) introducing the expression vector into a host cell to prepare a transformant; (c) inducing expression of a single chain antibody fragment (scFv)-ferritin fusion protein by culturing the transformant; and (d) purifying nanoparticles formed by self-assembly of the expressed single-chain antibody fragment-ferritin fusion protein;
- the present invention also provides a pharmaceutical composition for improving or treating a disease comprising the nanoparticles.
- the disease may be specified differently depending on the type of the single-chain antibody fragment, and when the single-chain variable fragment is derived from Bevacizumab, cancer (especially colon cancer, lung cancer, Glioblastoma, renal cell carcinoma) or eye disease (eg, macular degeneration) may be the target disease to be treated (target disease).
- cancer especially, breast cancer or metastatic gastric cancer
- target disease target disease
- the target disease may include, but is not limited to, cancers such as breast cancer, ovarian cancer, and ovarian cancer.
- the present invention provides a method for preventing or treating a target disease comprising administering the self-assembled nanoparticles.
- the therapeutically effective amount is the type and extent of the response to be achieved, the specific composition including whether other agents are used if necessary, the individual's age, weight, general health status, sex and diet, administration time, administration route, and composition It is preferable to apply differently depending on various factors including the secretion rate, treatment period, and drugs used or concurrently with a specific composition and similar factors well known in the pharmaceutical field. Therefore, it is preferable to determine the effective amount of the composition suitable for the purpose of the present invention in consideration of the foregoing.
- the subject is applicable to any mammal, and the mammal includes not only humans and primates, but also domestic animals such as cattle, pigs, sheep, horses, dogs and cats.
- the vector for preparing self-assembled nanoparticles or fusion proteins according to the present invention can significantly enhance the water-soluble expression of single-chain variable fragment-ferritin fusion proteins and self-assembled nanoparticles in host cells, and the production efficiency can be increased.
- the fusion protein expressed according to the vector of the present invention forms nanoparticles through self-assembly, and the formed nanoparticles present a single-chain variable fragment on the surface (surface expression), It is highly chemical and thus increases the efficiency of various immune responses, and thus can be used as a vaccine and therapeutic agent.
- FIG. 1 is a schematic diagram of a vector encoding a fusion protein according to the present invention.
- FIG. 1A shows a case in which scfv is derived from Bevacizumab
- FIG. 1B is a case in which scfv is derived from Trastuzumab
- FIG. 2B shows a case in which scfv is derived from Pertuzumab.
- FIG. 2 shows the structure of the linker according to the type of scfv and the three-dimensional structure when the linker is combined with scfv according to an embodiment of the present invention.
- FIG. 3 is an image confirming the solubility of RID and scfv fusion proteins.
- Figure 3a shows the water solubility of the hRID-Bevacizumab scfv-ferritin fusion protein
- Figure 3b shows the water solubility of the hRID-Trastuzumab scfv- ferritin fusion protein
- Figure 3c shows the water solubility of the hRID-pertuzumab scfv- ferritin fusion protein.
- FIG. 4 is an image confirming the separation of hRID-Bevacizumab scfv-ferritin fusion protein.
- Figure 4a the chromatogram results when the hRID-Bevacizumab scfv- ferritin fusion protein eluted by nickel affinity chromatography was purified by ion resin exchange chromatography was confirmed, and
- Figure 4b shows the results of size exclusion chromatography.
- 5 is an image confirming the separation of hRID-Trastuzumab scfv- ferritin fusion protein.
- 5a shows the chromatogram results when the hRID-Trastuzumab scfv-ferritin fusion protein eluted by nickel affinity chromatography was purified through ion resin exchange chromatography
- FIG. 5b shows the size exclusion chromatography results.
- 6 is an image confirming the isolation of hRID-pertuzumab scfv-ferritin fusion protein.
- 6a shows the chromatogram results when the hRID-pertuzumab scfv-ferritin fusion protein eluted by nickel affinity chromatography was purified through ion resin exchange chromatography, and
- FIG. 6b shows the size exclusion chromatography results.
- FIG. 7 is a transmission electron microscope image of nanoparticles formed by self-assembly of hRID-Bevacizumab scfv-ferritin fusion protein, hRID-Trastuzumab scfv-ferritin fusion protein, and hRID-pertuzumab scfv-ferritin fusion protein.
- 9 is a graph comparing the binding affinity of hRID-Bevacizumab scfv-ferritin (HFH; Human Ferritin heavy chain) fusion protein by ELISA analysis. 9 shows the folding and binding affinities of hRID(W)-Bevacizumab scfv-ferritin (HFH) fusion protein nanoparticles, hRID(9M)-Bevacizumab scfv-ferritin (HFH) fusion protein nanoparticles, and Bevacizumab scfv according to antibody concentration. indicates.
- HH Human Ferritin heavy chain
- FIG. 10 is a graph comparing the binding affinity of hRID-pertuzumab scfv-ferritin fusion protein nanoparticles to a target by SPR analysis.
- VEGF vascular endothelial growth factor
- FIG. 12 shows the choroidal flat-mount immunofluorescence image obtained 14 days after intravitreal injection of a drug into the eye of a mouse with laser-induced choroidal neovascularization and the average area of the measured choroidal neovascularization.
- 13 is a saline, 120nM ScFv, 600nM ScFv, 120nM ScFv-Ferritin, 600nM ScFv-Ferritin fusion protein nanoparticles into the eyes of mice, respectively, and the distribution of scFv in the retina on day 1 and day 7 using a confocal microscope. observed image.
- FIG. 14 shows the stability of fusion protein nanoparticles according to hRID.
- 14a shows the hRID-dependent stability of the hRID-Bevacizumab scfv-ferritin fusion protein nanoparticles
- FIG. 14b shows the hRID-dependent stability of the hRID-Trastuzumab scfv-ferritin fusion protein nanoparticles
- FIG. 14c shows the hRID-pertuzumab scfv-ferritin fusion
- the stability of protein nanoparticles according to hRID is compared.
- 15 is an image of purified fusion protein nanoparticles including hRID.
- 15A is an image showing the purification results of hRID-Bevacizumab scfv-ferritin fusion protein nanoparticles in the case of wild-type (w) and mutant hRID (9m), respectively, and
- FIG. 15B shows the results of size exclusion chromatography.
- 16 is an image showing the purification results of each hRID- Trastuzumab scfv-ferritin fusion protein nanoparticles in the case where hRID is wild-type (w) and mutant hRID (9m) in the protein.
- FIG. 17 shows TEM images of hRID-Bevacizumab scfv-ferritin fusion protein nanoparticles formed when hRID is wild-type (w) and mutant hRID (9m).
- FIG. 18 is a graph comparing the binding affinity of hRID-Bevacizumab scfv-ferritin (HFL; Human Ferritin light chain) fusion protein by indirect ELISA analysis.
- Figure 18 shows the folding of hRID(W)-Bevacizumab scfv-ferritin (HFL) fusion protein nanoparticles, hRID(9M)-Bevacizumab scfv-ferritin (HFL) fusion protein nanoparticles and Bevacizumab scfv according to the antibody concentration and binding to the target. indicates affinity.
- FIG. 19 shows the target binding affinity of hRID-scFv-G3SG3TG3SG3-ferritin (scFv-HFL) nanoparticles, hRID-scFv (scFv) and hRID-HFL (HFL) according to an embodiment of the present invention; It is a graph analyzed by sandwich ELISA. The results were obtained by repeating the ELISA three times.
- FIG. 20 is a schematic diagram showing a structure in which the fusion protein prepared according to an embodiment of the present invention forms nanoparticles by self-assembly.
- blue represents an antibody heavy chain variable fragment of scfv
- red represents an antibody light chain variable fragment.
- the present invention provides a polynucleotide encoding a single-chain variable fragment; peptides for enhancing the expression efficiency of single-chain variable fragments; and ferritin bound to the 3'-end of the polynucleotide encoding a single-chain variable fragment; provides an expression vector for preparing self-assembled nanoparticles comprising.
- FIGS. 1A to 1C are structures of an expression vector according to the present invention ( FIGS. 1A to 1C ), wherein hRID is cleaved after promoting solubility and folding of a single-chain variable fragment-ferritin fusion protein monomer. Thereafter, the monomer may be appropriately folded to form a trimer structure, and eight trimers may be assembled to form nanoparticles. That is, according to the present invention, the nanoparticles of the present invention may contain one or more and 24 or less single-chain variable fragment-ferritin fusion protein monomers, and preferably, the fusion protein monomer is a trimer. , nanoparticles including the 8 trimers (including a total of 24 fusion protein fragments) can be prepared. On the surface of the nanoparticles, 24 single-chain variable fragment-ferritin fusion proteins can be expressed on the surface.
- antibody includes immunoglobulin molecules having antigen-binding ability with reactivity with a specific antigen, and includes both polyclonal and monoclonal antibodies.
- the term also includes forms produced by genetic engineering such as chimeric antibodies (eg, humanized murine antibodies) and heterologous antibodies (eg, bispecific antibodies).
- Antibodies are structurally composed of heavy and light chains, each of which includes a constant region and a variable region.
- the variable regions of the heavy and light chains include three variable regions called “complementarity determining regions (CDRs)” and four “framework regions”.
- single chain variable fragment is not a general fragment formed from an antibody, but a fragment including the variable region of the heavy chain constituting the antibody and the variable region of the light chain. It is a fusion protein constructed by artificially fusing fragments containing
- the type of the single-chain antibody fragment is not limited as long as the nucleic acid or amino acid sequence is known.
- they are single-chain antibody fragments of Trastuzumab, Bevacizumab and Pertuzumab.
- the "single-chain variable fragment” of the present invention is a protein that those skilled in the art want to produce in large quantities, and inserts a polynucleotide encoding the protein into a recombinant expression vector to produce all proteins that can be expressed in a host cell. it means.
- "single-chain variable fragment” is expressed in a fusion form with ferritin in a host cell and may be located on the surface of nanoparticles self-assembled by ferritin.
- the "peptide for enhancing the expression efficiency of single-chain variable fragment" of the present invention can express a fusion protein of single-chain variable fragment and ferritin in a water-soluble form
- a fusion protein of single-chain variable fragment and ferritin in a water-soluble form
- Glutathione S transferase GST
- maltose binding protein ubiquitin
- taoredoxin etc.
- fusion proteins such as rRID, mRID, hRID, LysRS, and most preferably
- rRID mRID
- hRID hRID
- LysRS a fusion protein
- it may be configured to include the amino acid sequence of an N-terminal domain (hLysRS N-terminal appended RNA interacting domain; hRID) isolated from a human-derived lysyl tRNA synthetase.
- RID RNA interaction domain
- tag-RID represented by SEQ ID NO: 1 in which a tag sequence is bound to RID was used as a binding partner for soluble expression of single-chain antibody fragments (scFv) in bacteria.
- a doublemutant hRID mutated (K19A, K23A) for K19 and K23 sites among 9 hRID domains and nine mutant hRIDs mutated with K19A, K23A, R24A, K27A, K30A, K31A, K35A, K38A, and K40A were created.
- ferritin may be used without limitation as long as each of these proteins has an activity capable of forming a cage-type complex protein as a unit.
- the ferritin protein or fragment is not limited as long as the activity capable of forming a cage-type complex protein is maintained, and HFL (human ferritin light chain) or HFH (human ferritin heavy chain) may be used.
- the ferritin protein or fragment thereof of the present invention may be a protein or fragment formed by partially adding, deleting, or substituted amino acid residues in the amino acid sequence of SEQ ID NO: 2.
- expression vector is a linear or circular DNA molecule consisting of fragments encoding a polypeptide of interest operably linked to additional fragments that serve for transcription of the expression vector. Such additional fragments include promoter and terminator sequences.
- the expression vector also comprises one or more origins of replication, one or more selectable markers, polyadenylation signals, and the like. Expression vectors are generally derived from plasmid or viral DNA, or contain elements of both.
- operably linked refers to the arrangement of fragments in a promoter to act to initiate transcription and progress through the coding sequence to the termination code.
- the expression vector may be a plasmid, a viral vector, a phage particle or a genome insert. After the expression vector is transformed into a host cell, it can be cloned independently of the genome of the host cell or integrated into the genome of the host cell.
- the vector may be constructed by further including a linker between the polynucleotide encoding a single-chain variable fragment and ferritin.
- the linker is for attaching the single-chain antibody fragment (scFv) to a specific site at the C-terminus or N-terminus of the ferritin monomer fragment, and may consist of one to several amino acids.
- the linker is introduced between the single-chain variable fragment and ferritin to minimize steric hindrance between the two domains, thereby improving the formation of trimeric and nanoparticle structures.
- the nanoparticles are formed by the precise self-assembly of low-molecular-weight monoliths (monomers) and refer to cage-type particles made of proteins having a space therein.
- the nanoparticles of the present invention are characterized in that they contain the single-chain antibody fragment (scFv)-ferritin fusion protein of the present invention as a unit constituting the cage.
- self-assembly refers to the property of certain molecules to form specific nanostructures on their own without a special external stimulus or artificial induction.
- the eight trimers are regularly arranged three-dimensionally, This may be formed by gathering 24 monomers.
- a nucleic acid encoding a single-chain variable fragment-ferritin fusion protein or a recombinant vector containing the nucleic acid can transform or transfect a host cell.
- nucleic acid or “polynucleotide” refers to deoxyribonucleotides or ribonucleotides in single or double-stranded form. Unless otherwise limited, known analogs of natural nucleotides that hybridize to nucleic acids in a manner analogous to naturally occurring nucleotides are also included.
- the term "recombinant protein” or “fusion protein” refers to a single-chain antibody fragment (scFv) sequence in which another protein is linked to the N-terminus or C-terminus or has a different amino acid sequence.
- the added protein preferably a monomeric protein (scFv-ferritin monomer) in which a single-chain antibody fragment (scFv) is bound to the N-terminus of the ferritin protein, or a single-chain antibody fragment ( scFv) and hRID to single-chain antibody fragment (hRID-scFv-ferritin monomer).
- protein is used interchangeably with “peptide” or “polypeptide”, eg, refers to a polymer of amino acid residues as commonly found in naturally occurring proteins.
- the recombinant vector of the present invention can be obtained by linking (inserting) the nucleic acid of the present invention to an appropriate vector.
- the vector into which the nucleic acid of the present invention is inserted is not particularly limited as long as it can be replicated in a host.
- plasmid DNA, phage DNA, and the like can be used.
- Specific examples of the plasmid DNA include commercial plasmids such as pCDNA31+ (Invitrogen).
- Other examples of plasmids that can be used in the present invention include E.
- coli-derived plasmids pYG601BR322, pBR325, pUC118 and pUC119
- Bacillus subtilis-derived plasmids pUB110 and pTP5
- yeast-derived plasmids YEp13, YEp24 and YCp50.
- phage DNA include ⁇ -phages (Charon4A, Charon21A, EMBL3, EMBL4, ⁇ gt10, ⁇ gt11 and ⁇ ZAP).
- retroviruses animal viruses such as adenoviruses or vaccinia viruses, insect viruses such as baculoviruses can also be used.
- a method of cutting the purified DNA with an appropriate restriction enzyme and inserting it into an appropriate restriction site or cloning site of the vector DNA may be used.
- the nucleic acid of the present invention is preferably operably linked to a vector.
- the vector of the present invention includes a cis element such as an enhancer, a splicing signal, a poly A addition signal, and a selection marker. ), and may further include a ribosome binding sequence (SD sequence) and the like.
- SD sequence ribosome binding sequence
- chloramphenicol-resistant nucleic acid, ampicillin-resistant nucleic acid, dihydrofolate reductase, neomycin-resistant nucleic acid, etc. may be used, but the additional components operably linked by the above examples are limited not.
- the present invention provides a host cell transformed with the above-described expression vector.
- the term 'transformation' refers to introducing DNA into a host so that DNA can be replicated as a factor of chromosomes or by chromosomal integration completion. It refers to a phenomenon that causes change.
- transformation methods include CaCl2 precipitation, the CaCl2 method using a reducing material called DMSO (dimethyl sulfoxide), the Hanahan method with increased efficiency, electroporation, calcium phosphate precipitation, protoplast fusion, silicon carbide
- DMSO dimethyl sulfoxide
- electroporation calcium phosphate precipitation
- protoplast fusion silicon carbide
- agitation method using fiber agrobacterium mediated transformation method
- transformation method using PEG dextran sulfate
- lipofectamine lipofectamine
- the method for transforming the single-chain variable fragment (Single-chain variable fragment)-ferritin fusion protein-encoding nucleic acid or vector comprising the same of the present invention is not limited to the above examples, and transformation commonly used in the art Alternatively, the transfection method may be used without limitation.
- the transformant of the present invention can be obtained by introducing a target nucleic acid, a single-chain variable fragment, a nucleic acid encoding a ferritin fusion protein or a recombinant vector containing the same into a host.
- the host is not particularly limited as long as it allows expression of the nucleic acid of the present invention.
- Specific examples of the host that can be used in the present invention include Escherichia bacteria such as E coli; Bacillus genus bacteria such as Bacillus subtilis; Bacteria of the genus Pseudomonas such as Pseudomonas putida; lactic acid bacteria such as Lactobacillus and Enterococcus; Yeasts such as Saccharomyces cerevisiae, Schizosaccharomyces pombe; There are prokaryotic cells, animal cells, and insect cells.
- eukaryotic cells such as yeast, insect, and mammalian cells have been preferred over E. coli due to auxiliary folding, post-translational modification, and the possibility of generating multi-component nanoparticles.
- a self-assembled nanoparticle structure marked with a single-chain variable fragment was produced using E. coli, which is inexpensive and easily mass-produced.
- the host cell of the present invention is not limited thereto, but may be E. coli in terms of inexpensive and easy mass production.
- the recombinant vector of the present invention is capable of autonomous replication in the host, and is composed of a promoter, a ribosome binding sequence, a nucleic acid of the present invention and a transcription termination sequence. have.
- any promoter may be used as long as the nucleic acid of the present invention is expressed in a host such as E. coli.
- E. coli or phage-derived promoters such as trp promoter, lac promoter, PL promoter or PR promoter; E. coli infected phage-derived promoters such as the T7 promoter can be used.
- An artificially modified promoter such as the tac promoter may also be used.
- the present invention provides (a) a polynucleotide encoding a single-chain variable fragment; preparing an expression vector comprising a peptide for enhancing the expression efficiency of the single-chain variable fragment; and a polynucleotide encoding ferritin; (b) introducing the expression vector into a host cell to prepare a transformant; (c) inducing expression of a single-chain variable fragment-ferritin fusion protein by culturing the transformant; and (d) purifying the nanoparticles formed by the self-assembly of the expressed single-chain variable fragment-ferritin fusion protein; provides a method for producing self-assembled nanoparticles comprising a.
- the plasmid vector may further include other sequences if necessary.
- the sequence that may be further included may be a tag sequence for protein purification, for example, glutathione S-transferase (Pharmacia, USA), MBP (maltose binding protein, USA), FLAG (IBI, USA) and hexahistidine ( hexahistidine; Quiagen, USA), and most preferably hexahistidine, but the types of sequences required for purification of single-chain variable fragments are not limited by the above examples.
- a fusion protein expressed by a vector containing the fusion sequence it may be purified by affinity chromatography.
- glutathione-S-transferase when glutathione-S-transferase is fused, glutathione, a substrate of this enzyme, can be used, and when MBP is used, the desired single-chain antibody fragment (scFv) can be easily recovered using an amylose column.
- scFv single-chain antibody fragment
- the single-chain variable fragment (Single-chain variable fragment)-ferritin fusion protein of the present invention transformed by the above method to express the host cell can be cultured by a conventional method used in the art.
- the transformant expressing the single-chain variable fragment-ferritin fusion protein can be cultured in various media, and fed-batch culture and continuous culture can be performed.
- the method for culturing the transformant of the present invention is not limited by the above example.
- the carbon source that can be included in the medium for the growth of host cells can be appropriately selected by the judgment of a person skilled in the art according to the type of transformant prepared, and appropriate culture conditions can be adopted to control the culture period and amount.
- the transformant successfully transformed with a single-chain variable fragment produces a single-chain variable fragment-ferritin fusion protein.
- the single-chain variable fragment-ferritin fusion protein produced according to the composition of the vector and the characteristics of the host cell can be secreted into the cytoplasm of the host cell, the periplasmic space or the extracellular space.
- Proteins expressed in or outside the host cell can be purified in a conventional manner.
- purification methods include salting out (eg, ammonium sulfate precipitation, sodium phosphate precipitation, etc.), solvent precipitation (eg, protein fraction precipitation using acetone, ethanol, etc.), dialysis, gel filtration, ion exchange, reversed-phase column chromatography
- the protein of the present invention can be purified by applying techniques such as chromatography and ultrafiltration alone or in combination.
- the present invention provides nanoparticles prepared by the above manufacturing method.
- the single-chain variable fragment-ferritin fusion protein according to the present invention can form spherical nanoparticles by self-assembly of 24 monomers.
- the diameter of the nanoparticles may be 24 to 30 nm.
- the present invention provides a pharmaceutical composition for preventing, improving or treating a disease comprising the nanoparticles.
- prevention refers to any action that suppresses or delays the onset of a target disease by administration of the composition
- treatment refers to any action in which the symptoms of the target disease are improved or beneficially changed by the composition.
- the "disease” may be specified differently depending on the type of single-chain variable fragment used.
- the single-chain variable fragment is derived from Bevacizumab
- cancer especially colorectal cancer, lung cancer, glioblastoma, renal cell cancer
- eye disease eg, macular lesions
- the single-chain variable fragment is derived from Trastuzumab
- cancer especially breast cancer or metastatic gastric cancer
- the single-chain variable fragment is derived from Pertuzumab
- cancers such as breast cancer, ovarian cancer, and ovarian cancer may be included as target diseases.
- the pharmaceutical composition according to the present invention may contain the nanoparticles alone or may be formulated in a suitable form together with a pharmaceutically acceptable carrier, and may further contain excipients or diluents.
- a pharmaceutically acceptable carrier may further contain excipients or diluents.
- the term 'pharmaceutically acceptable' refers to a non-toxic composition that is physiologically acceptable and does not normally cause allergic reactions such as gastrointestinal disorders, dizziness, or similar reactions when administered to humans.
- the pharmaceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration.
- Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like.
- the carrier for parenteral administration may include water, a suitable oil, saline, aqueous glucose and glycol, and the like, and may further include a stabilizer and a preservative.
- Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid.
- Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol.
- the pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, and the like, in addition to the above components.
- a lubricant for other pharmaceutically acceptable carriers and agents, reference may be made to those described in the following literature (Remington's Pharmaceutical Sciences, 19th ed, Mack Publishing Company, Easton, PA, 1995).
- composition of the present invention can be administered to mammals including humans by any method.
- it may be administered orally or parenterally.
- Parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual or rectal administration.
- the pharmaceutical composition of the present invention may be formulated as a formulation for oral administration or parenteral administration according to the administration route as described above.
- the composition of the present invention may be formulated as a powder, granule, tablet, pill, dragee, capsule, liquid, gel, syrup, slurry, suspension, etc. using methods known in the art.
- oral preparations can be obtained by mixing the active ingredient with a solid excipient, pulverizing it, adding a suitable adjuvant, and processing it into a granule mixture to obtain tablets or dragees.
- excipients include sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, and starches, including corn starch, wheat starch, rice starch and potato starch, cellulose, Cellulose, including methyl cellulose, sodium carboxymethylcellulose and hydroxypropylmethyl-cellulose, and the like, fillers such as gelatin, polyvinylpyrrolidone, and the like may be included.
- cross-linked polyvinylpyrrolidone, agar, alginic acid or sodium alginate may be added as a disintegrant if necessary.
- the pharmaceutical composition of the present invention may further include an anti-aggregating agent, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent, and an antiseptic agent.
- Formulations for parenteral administration may be formulated in the form of injections, creams, lotions, external ointments, oils, moisturizers, gels, aerosols and nasal inhalants by methods known in the art. These formulations are described in Remington's Pharmaceutical Science, 19th ed, Mack Publishing Company, Easton, PA, 1995, a recipe commonly known to all pharmaceutical chemistry.
- the total effective amount of the composition of the present invention may be administered to a patient as a single dose, or may be administered by a fractionated treatment protocol in which multiple doses are administered for a long period of time.
- the pharmaceutical composition of the present invention may vary the content of the active ingredient depending on the severity of the disease.
- the preferred total dose of the pharmaceutical composition of the present invention may be about 001 ⁇ g to 10,000 mg, most preferably 0.1 mg to 500 mg per kg of body weight of the patient per day.
- the dosage of the pharmaceutical composition is determined by considering various factors such as the formulation method, administration route and number of treatments, as well as the patient's age, weight, health status, sex, severity of disease, diet and excretion rate, etc., the effective dosage for the patient is determined.
- the pharmaceutical composition according to the present invention is not particularly limited in its formulation, administration route and administration method as long as the effect of the present invention is exhibited.
- hRID RNA interaction domain originated from human
- pGE -hRID vector was digested with SalI and Hind2 restriction enzymes, and a ferritin gene derived from a microorganism or human was inserted to create a hRID-FR vector.
- the hRID-FR vector was digested with KpnI and SalI restriction enzymes, and the amino acid SGGGGSGGGG was inserted as a linker between the ScFv sequence ferritin of bevacizumab to construct a vector composed of a TEV cleavage site and 6x-His-Bevacizumab ScFv-FR in hRID.
- the pGE-hRID vector was digested with KpnI and EcoRV restriction enzymes, and GGGG SGGGGSGGGGSGQAGQHAAGSGSGSS was inserted as a linker between the ScFv of Trastuzumab and the human-derived ferritin gene.
- the constructed vector was constructed.
- the hRID-FR vector was digested with BamHI and SalI restriction enzymes, and GGGSGGGTGGGSGGG was inserted as a linker between the ScFv sequence of Pertuzumab and Ferritin to construct a vector composed of a TEV cleavage site and 6x-His-Trastuzumab ScFv-FR in hRID.
- IPTG isopropyl ⁇ -D-1-thioglalactopyranoside
- the wash buffer [50 mM Tris-HCl (pH 8.0), 0, 100, 200, 300 mM NaCl, 10% glycerol, 2.86 mM 2-mercaptoethanol, TWEEN-20 0.1%] was used, T (Total), the supernatant obtained by centrifugation of the lysed cells at 4 °C, 20 minutes, 12000 rpm is used as S (Soluble), and the submerged cells are used as P (Pellet). Water solubility was confirmed.
- IPTG isopropyl ⁇ -D-1-thioglalactopyranoside
- the wash buffer [50 mM Tris-HCl (pH 8.0), 0, 100, 200, 300 mM NaCl, 10% glycerol, 2.86 mM 2-mercaptoethanol, TWEEN-20 0.1%] was used, T (Total), the supernatant obtained by centrifugation of the lysed cells at 4 °C, 20 minutes, 12000 rpm is used as S (Soluble), and the submerged cells are used as P (Pellet). Water solubility was confirmed.
- IPTG isopropyl ⁇ -D-1-thioglalactopyranoside
- Nanoparticle protein (3ml) was placed in Dispo-H cell, and size was measured and analyzed (DLS) using Zeta-potential & Particle size Analyzer (ELS-2000ZS; Otsuka Electronics). The intensity distribution diameter of nanoparticles was measured twice in a water solvent at 25°C, and the sample accumulation time was measured at 200 seconds.
- FIG. 8 is a view of thermal stability analysis of a control material and nanoparticles
- FIG. 5 is a control material scFv, Bevacizumab, and h-scFV-HFH (of nanoparticles) using circular dichroism (CD) spectroscopy.
- CD circular dichroism
- Example 1-1 SPR and ELISA analysis of bevacizumab-ferritin fusion protein
- a Biacore T100 analyzer (GE Healthcare, Uppsala, Sweden) was used.
- a CM5 sensor chip (GE Healthcare) activated with EDC/NHS (N'-(3-dimethylaminopropyl) carbodiimide hydrochloride / N-hydroxysuccinimide) was used.
- EDC/NHS N'-(3-dimethylaminopropyl) carbodiimide hydrochloride / N-hydroxysuccinimide
- VEGF protein 10 ⁇ g/ml in 10 mM sodium acetate, pH 5.0
- the activated portion remaining on the surface of the sensor chip was inactivated by adding 1.0 M ethanolamine (ethanolamine, pH 8.5).
- bevacizumab or scFv-ferritin fusion protein was diluted in a buffer solution (1 X PBS, pH 7.4) for each concentration, and the binding and dissociation sensorgrams were checked while flowing at a flow rate of 30 ⁇ l/min.
- a buffer solution (1 X PBS, pH 7.4) for each concentration
- BSA bovine serum albumin
- the Bevacizumab-ferritin fusion protein has more binding strength than the Bevacizumab-ferritin fusion protein without hRID mutation. This was done to determine whether it decreased. 2000 nM/well hVEGF protein (Abcam) was coated onto Nunc 96-well microtiter immunoplates (Thermo Fisher Scientific) overnight at 4°C. Between all procedures, the immunoplates were washed 3 times with PBST (0.05% Tween 20 added to PBS) wash buffer.
- PBST 0.05% Tween 20 added to PBS
- hRID(W)-scFV-HFH, hRID(9m)-scFv-HFH,scFv were serially diluted in half from 100 nM to 0.19 nM using PBST. The diluted material was applied to immunoplates and incubated for 2 hours. Then, 100 ⁇ l of 1/400 of anti-hVEGF mAb was added to each well at 37° C. and incubated for 2 hours.
- the wells were treated with anti-mouseIgG conjugated with peroxidase diluted by 1/20000 in serum dilution buffer (PBST+0.5%BSA) and incubated for 2 hours. Finally, 100 ⁇ l/well of substrate TMB solution (BD Biosciences) was incubated in the dark at 37° C. for 30 minutes. To stop the color reaction, 50 ⁇ l of a stop solution (2NH2SO4) was added to the wells, and absorbance was measured at 450 ⁇ M using an ELISA reader FLUOstar OPTIMA (BMG LABTECH).
- 18 is a graph comparing the binding affinity of hRID-Bevacizumab scfv-ferritin (HFL; Human Ferritin light chain) fusion protein by indirect ELISA analysis. 18 shows the folding and target binding affinity of hRID(W)-Bevacizumab scfv-ferritin (HFL) fusion protein, hRID(9M)-Bevacizumab scfv-ferritin (HFL) fusion protein, and Bevacizumab scfv according to antibody concentration. .
- FIG. 19 is a sandwich ELISA showing the target binding affinity of hRID-scFv-G3SG3TG3SG3-ferritin (scFv-HFL), hRID-scFv (scFv) and hRID-HFL (HFL) according to an embodiment of the present invention; It is a graph analyzed by The results were obtained by repeating the ELISA three times.
- ferritin exists in two types (HFH/HFL) according to its size.
- FIGS. 18 and 19 it can be seen that the fusion protein prepared according to the present invention has an increased affinity for the target by self-assembly regardless of the size/type of ferritin.
- hRID-scFv-G3SG3TG3SG3-ferritin (scFv-HFL) fusion protein nanoparticles or Bevacizumab-ferritin (HFH) fusion protein nanoparticles hRID-scFv (scFv) at a concentration of 24 times Or it can be seen that it binds to more antigens than when using hRID-HFL (HFL).
- the fusion protein of the present invention forms nanoparticles and has a binding affinity to the target than when using a monomer structure that does not form nanoparticles (eg, hRID-scFv (scFv) or hRID-HFL (HFL)). It can be seen that is higher
- Example 1-2 ELISAX, SPR analysis of Trastuzumab-ferritin fusion protein nanoparticles (Fig. 10)
- the binding force between Trastuzumab, the prototype of scFv, and HER2 and the binding force between the scFv-ferritin fusion protein nanoparticles and HER2 were compared using SPR (Surface plasmon resonance) analysis.
- a Biacore T100 analyzer (GE Healthcare, Uppsala, Sweden) was used.
- a CM5 sensor chip (GE Healthcare) activated with EDC/NHS (N'-(3-dimethylaminopropyl) carbodiimide hydrochloride/N-hydroxysuccinimide) was used.
- EDC/NHS N'-(3-dimethylaminopropyl) carbodiimide hydrochloride/N-hydroxysuccinimide
- HER2 protein (10 ⁇ g/ml in 10 mM sodium acetate, pH 5.0) was flowed for 5 minutes to immobilize it.
- the activated part remaining on the surface of the sensor chip was inactivated by adding 1.0 M ethanolamine (ethanolamine, pH 8.5).
- the Herceptin or scFv-ferritin fusion protein nanoparticles were diluted in buffer solution (1 X PBS, pH 7.4) for each concentration, and the binding and dissociation sensorgrams were checked while flowing at a flow rate of 30 ⁇ l/min ( Fig. 9).
- buffer solution (1 X PBS, pH 7.4
- BSA bovine serum albumin
- HUVECs were maintained in a serum starvation state for 6 hours, and VEGF, VEGF+Avastin, VEGF+G6 monomer, and VEGF+G6 24-mer were treated in the lower part of the transwell plate at the concentrations shown in the figure, and 1x10 5 cells were seeded in the transwell. After 5 hours, cells that had migrated to the transwell were identified through H&E staining (top of FIG. 11 ).
- HUVECs were maintained in a serum starvation state for 6 hours, and 1.3x10 5 cells were mixed with each of VEGF, VEGF+Avastin, VEGF+G6 monomer, and VEGF+G6 24-mer treated at the concentrations shown in the figure on a matrigel-coated plate.
- Angiogenesis was confirmed 18 hours after planting (bottom of FIG. 11).
- the scFv monomer showed the same effect as Avastin at the same concentration on vascular endothelial cell mobility and angiogenesis, and showed a stronger effect than Avastin in the multimer (G6 24-mer).
- the inhibitory effect of vascular endothelial cell mobility and angiogenesis to VEGF was superior to that of the VEGF-treated control group. can confirm.
- the laser-induced CNV animal model focuses on the fundus retina and retinal pigment layer using argon green laser, an ophthalmic laser treatment equipment, on 24 8-week-old males of C57BL/6 mouse 8 weeks. At 100mW, try 4-5 laser photo coagulation. On the day of laser treatment, 4-5 animals in each group were intraocularly injected with 4 experimental groups (120nM ScFv monomer, 600nM scFv, 120nM ScFv-Ferritin, 600nM ScFv-Ferritin) and a normal control (vehicle).
- Anti-Glial fibrillary acidic protein antibody for the purpose of confirming the distribution of astrocytes by counterstaining to confirm the structure in the retina, Lectin-PNA Alexa 488 (Molecular Probes, Eugene, After cross-fluorescence staining was performed using an antibody such as OR, USA), the distribution of scFV nanoparticles was confirmed for each group in each retinal layer by photographing under a confocal fluorescence microscope (LSM710; Carl Zeiss, Jena, Germany). (See Fig. 13). scFv was stained using His tag antibody (red color).
- scFv-Ferritin fusion protein nanoparticles can maintain a strong and lasting therapeutic effect for a longer period of time by attaching to the inner layer surface of the retina at a high concentration and delivering scFv to the inner layer surface and the entire retinal layer for a long time compared to scFv alone administration.
- Example 5-1 Bevacizumab fusion protein nanoparticles
- RNA functions like molecular chaperones in E. coli, helping to improve protein solubility and folding. So, to confirm this, a point mutation (9m) was made to prevent tRNA from binding to the representative hRID of Chaperna. SDS PAGE by expressing hRID(w)-Bevacizumab-ferritin, a wild-type hRID (w) form, and hRID(9m)-Bevacizumab-ferritin, a form mutated (9m) to prevent tRNA binding to hRID. The GEL was lowered to compare the solubility of proteins.
- Example 5-2 Trastuzumab fusion protein nanoparticles
- Trastuzumab-ferritin a form in which hRID is not bound, hRID(WT)-Trastuzumab-ferritin, a form in which hRID is wild-type (WT), and hRID (9m), a form in which mutations (9m) are given to prevent tRNA binding to hRID (9m) -Trastuzumab-ferritin was expressed and the SDS PAGE GEL was lowered to compare the protein solubility. It was confirmed that the protein to which hRID was not bound was not expressed in E. coli, whereas the protein to which hRID was bound was expressed. In addition, it was confirmed that, even if hRID is bound to a protein, water solubility is very poor if tRNA is not bound to hRID.
- Example 5-3 Pertuzumab fusion protein nanoparticles
- Pertuzumab-ferritin a form in which hRID is not bound
- hRID (WT)-Pertuzumab-ferritin a form in which hRID is wild-type (WT)
- SDS PAGE GEL was lowered to compare protein solubility.
- the protein to which hRID is not bound at all was expressed in E. coli, the water solubility was not increased at any NaCl concentration, but it was confirmed that the protein to which hRID was bound increased the water solubility of the protein according to the NaCl concentration.
- Example 6-1 Bevacizumab fusion protein nanoparticles (Fig. 15 a, b)
- hRID(w)-Bevacizumab-ferritin and the form of hRID(9m)-Bevacizumab-ferritin were expressed and purified to see what role RNA binding plays in the formation of nanoparticles. proceeded.
- Example 6-2 Trastuzumab fusion protein nanoparticles ( FIG. 16 )
- RNA binding in the formation of nanoparticles in the form of Trastuzumab-ferritin, hRID(w)- Trastuzumab-ferritin, and hRID(9m)- Trastuzumab-ferritin form was expressed and purified. It was confirmed that the protein not bound to hRID was not purified.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Tag-hRID(W) amino seq | MSEQHAQAAVQAAEVKVDGSEPKLSKNELKRRLKAEKKVAEKEAKQKELSEKQLSATAAATNHTTDNGVGPEEESV |
Tag-hRID(2m) amino seq(K19A/K23A) | MSEQHAQAAVQAAEVKVDGSEPKLSKNEL A RRL A AEKKVAEKEAKQKELSEKQLSATAAATNHTTDNGVGPEEESV |
Tag-hRID(9m) amino seq(K19A/K23A/R24A/K27A/K30A/K31A/K35A/K38A/K40A) | MSEQHAQAAVQAAEVKVDGSEPKLS A NEL AA RL A AE AA VAE A EA A Q A ELSEKQLSATAAATNHTTDNGVGPEEESV |
Antigen | Antibody | Ka (1/Ms) | Kd (1/s) | KD (M) |
Human VEGF | Bevacizumab | 1.786E+5 | 4.021E-6 | 2.251E-11 |
scFv monomer | 4.574E+4 | 5.682E-4 | 1.242E-8 | |
h(3)-scFv-HFH | 4.655E+5 | 4.424E-5 | 9.503E-11 | |
h(3)-scFv-HFH +chaperone |
3.813E+4 | 2.577E-6 | 1.241E-11 | |
Mouse VEGF | Bevacizumab | ND | ND | ND |
scFv monomer | 4.859E+4 | 8.971E-4 | 1.846E-8 | |
h(3)-scFv-HFH | 7.441E+4 | 3.686E-6 | 4.953E-11 | |
h(3)-scFv-HFH +chaperone |
9.727E+4 | 1.248E-6 | 1.283E-11 |
Claims (16)
- 페리틴(ferritin) 단백질;상기 페리틴 단백질의 N-말단에 결합된, 단일사슬항체조각(Single-chain fragment variable); 및상기 단일사슬항체조각의 N-말단에 결합된, 인간 유래 라이실 tRNA 합성효소로부터 분리한 N-말단 도메인(hLysRS Nterminal appended RNA interacting domain; hRID)을 포함하는 융합단백질.
- 제1 항에 있어서,상기 단일사슬항체조각은 트라스투주맙(Trastuzumab), 베바시주맙(Bevacizumab) 및 퍼투주맙(pertuzumab)으로 이루어진 군에서 선택된 어느 하나의 항체로부터 유래된 것인, 융합단백질.
- 제1 항에 있어서,상기 hRID는 서열번호 1의 아미노산 서열로 표시되는 것인, 융합단백질.
- 제1 항에 있어서,상기 페리틴 단백질은 서열번호 4의 아미노산 서열로 표시되는 것인, 융합단백질.
- 제1 항에 있어서,상기 융합단백질은 단일사슬항체조각(scFv) 및 페리틴 단백질 사이에 링커 단백질를 더 포함하는 것인 융합단백질.
- 제5 항에 있어서,상기 링커 단백질은 서열번호 8 내지 10의 아미노산 서열 중 어느 하나로 표시되는 아미노산 서열을 갖는, 융합단백질.
- 제1 항의 융합단백질을 단량체로 하여 2개 내지 24개가 자가조립되어 형성되는 나노입자.
- 제1 항의 융합단백질을 코딩하는 폴리뉴클레오티드.
- 제8 항의 폴리뉴클레오티드를 포함하는 재조합 발현 벡터.
- 제9 항에 따른 발현 벡터로 형질 전환된 숙주세포.
- 제10 항에 있어서,상기 숙주세포는 에스케리키아(Escherichia)속 세균, 바실러스 (Bacillus)속 세균, 슈도모나스(Pseudomonas)속 세균, 유산균, 효모, 동물세포 및 곤충 세포로 이루어진 군에서 선택되는 것인 형질 전환된 숙주세포.
- (a) 페리틴(ferritin) 단백질; 및 상기 페리틴(ferritin) 단백질의 N-말단에 결합된 단일사슬항체조각(Single-chain variable fragment); 및 상기 단일사슬항체조각의 N-말단에 결합된, 인간 유래 라이실 tRNA 합성효소로부터 분리한 N-말단 도메인(hLysRS N-terminal appended RNA interacting domain; hRID) 으로 이루어진 융합단백질을 코딩하는 폴리뉴클레오티드를 포함하는 발현 벡터를 제조하는 단계;(b) 상기 발현 벡터를 숙주세포에 도입하여 형질전환체를 제조하는 단계;(c) 상기 형질전환체를 배양하여 상기 융합단백질의 발현을 유도하는 단계; 및(d) 상기 발현된 융합단백질의 자가조립에 의해 형성된 나노입자를 정제하는 단계;를 포함하는 나노입자의 제조방법.
- 제12 항에 있어서,상기 나노입자는 융합단백질을 단량체로 하여 2개 내지 24개가 자가조립되어 형성된 것인, 나노입자의 제조방법.
- 제12 항에 있어서,상기 단일사슬항체조각은, 트라스투주맙(Trastuzumab), 베바시주맙(Bevacizumab) 및 퍼투주맙(pertuzumab)으로 이루어진 군에서 선택된 어느 하나의 항체로부터 유래된 것인 나노입자의 제조방법.
- 제1 항의 융합단백질을 포함하는 질병의 개선 또는 치료용 약제학적 조성물.
- 표적질환을 치료하기 위한, 나노입자의 용도에 관한 것으로,상기 나노입자는, 페리틴(ferritin) 단백질; 상기 페리틴 단백질의 N-말단에 결합된, 단일사슬항체조각(Single-chain fragment variable); 및 상기 단일사슬항체조각의 N-말단에 결합된, 인간 유래 라이실 tRNA 합성효소로부터 분리한 N-말단 도메인(hLysRS Nterminal appended RNA interacting domain; hRID)을 포함하는 융합단백질이 단량체로서 2개 내지 24개가 자가조립되어 형성된 것을 특징으로 하는 나노입자의 용도.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020237042487A KR20240008333A (ko) | 2021-05-07 | 2022-05-09 | 단일사슬항체조각 및 페리틴의 융합단백질을 포함하는나노입자 및 이의 용도 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0059544 | 2021-05-07 | ||
KR20210059544 | 2021-05-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022235140A1 true WO2022235140A1 (ko) | 2022-11-10 |
Family
ID=83932822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/006597 WO2022235140A1 (ko) | 2021-05-07 | 2022-05-09 | 단일사슬항체조각 및 페리틴의 융합단백질을 포함하는 나노입자 및 이의 용도 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20240008333A (ko) |
WO (1) | WO2022235140A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117586425A (zh) * | 2024-01-19 | 2024-02-23 | 北京安百胜生物科技有限公司 | 一种重组呼吸道合胞病毒颗粒抗原其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100159442A1 (en) * | 2006-11-02 | 2010-06-24 | Iti Scotland Limited | Magnetic recognition system |
KR20160094550A (ko) * | 2015-01-30 | 2016-08-10 | 동국대학교 산학협력단 | 단일사슬항체조각과 페리틴을 포함하는 융합단백질 및 그의 용도 |
KR20180050261A (ko) * | 2018-04-27 | 2018-05-14 | 동국대학교 산학협력단 | 단일사슬항체조각과 바이러스 외피 단백질을 포함하는 융합단백질 및 이의 용도 |
KR102076917B1 (ko) * | 2018-10-25 | 2020-02-13 | 연세대학교 산학협력단 | 자가조립 나노 입자를 제조하기 위한 유전자 재조합 발현 벡터 시스템 및 이를 이용하는 방법 |
-
2022
- 2022-05-09 WO PCT/KR2022/006597 patent/WO2022235140A1/ko active Application Filing
- 2022-05-09 KR KR1020237042487A patent/KR20240008333A/ko unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100159442A1 (en) * | 2006-11-02 | 2010-06-24 | Iti Scotland Limited | Magnetic recognition system |
KR20160094550A (ko) * | 2015-01-30 | 2016-08-10 | 동국대학교 산학협력단 | 단일사슬항체조각과 페리틴을 포함하는 융합단백질 및 그의 용도 |
KR20180050261A (ko) * | 2018-04-27 | 2018-05-14 | 동국대학교 산학협력단 | 단일사슬항체조각과 바이러스 외피 단백질을 포함하는 융합단백질 및 이의 용도 |
KR102076917B1 (ko) * | 2018-10-25 | 2020-02-13 | 연세대학교 산학협력단 | 자가조립 나노 입자를 제조하기 위한 유전자 재조합 발현 벡터 시스템 및 이를 이용하는 방법 |
Non-Patent Citations (1)
Title |
---|
KIM YOUNG-SEOK, SON AHYUN, KIM JIHOON, KWON SOON BIN, KIM MYUNG HEE, KIM PAUL, KIM JIEUN, BYUN YOUNG HO, SUNG JEMIN, LEE JINHEE, Y: "Chaperna-Mediated Assembly of Ferritin-Based Middle East Respiratory Syndrome-Coronavirus Nanoparticles", FRONTIERS IN IMMUNOLOGY, vol. 9, 17 May 2018 (2018-05-17), XP055840832, DOI: 10.3389/fimmu.2018.01093 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117586425A (zh) * | 2024-01-19 | 2024-02-23 | 北京安百胜生物科技有限公司 | 一种重组呼吸道合胞病毒颗粒抗原其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
KR20240008333A (ko) | 2024-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016346864B2 (en) | Long-acting FGF21 fusion proteins and pharmaceutical composition comprising same | |
KR102155875B1 (ko) | 혈관신생 억제용 융합 단백질 | |
WO2016153276A1 (ko) | 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도 | |
WO2012165925A2 (ko) | Hgf 활성을 가지는 c-met에 대한 인간항체 및 이의 용도 | |
WO2019004799A1 (ko) | Vegf-grab 단백질과 약물의 결합체 및 이의 용도 | |
KR20240027854A (ko) | Tgf-β-수용체 엑토도메인 융합 분자 및 그의 용도 | |
WO2016114633A1 (en) | Long-acting fgf21 fusion proteins and pharmaceutical composition comprising the same | |
WO2022235140A1 (ko) | 단일사슬항체조각 및 페리틴의 융합단백질을 포함하는 나노입자 및 이의 용도 | |
WO2020091529A1 (ko) | 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물 | |
WO2021221470A1 (ko) | 인터페론-베타 변이체와 항체가 융합된 재조합 단백질 및 이를 포함하는 약학 조성물 | |
WO2021154046A1 (ko) | pH-감응성 FC 변이체 | |
WO2023214833A1 (ko) | Glp-1, 면역글로불린 fc, 및 igf-1을 포함하는 융합단백질 및 이의 용도 | |
WO2023055155A1 (ko) | 혈액 뇌장벽 투과용 펩타이드 및 이의 용도 | |
WO2020050626A1 (ko) | O-글리코실화 가능한 폴리펩타이드 영역을 포함하는 융합 폴리펩타이드 | |
WO2022164288A1 (ko) | 비염증성 식세포작용 유도 활성을 갖는 융합분자 | |
KR102352336B1 (ko) | 글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 융합단백질 및 이의 용도 | |
CN111819196A (zh) | 双特异性hiv-1中和抗体 | |
WO2018021778A1 (ko) | Lrg1 당단백질을 포함하는 융합 단백질을 함유하는 발기부전, 허혈성 질환 또는 말초 신경질환의 예방 또는 치료용 조성물 | |
AU2022316521B2 (en) | A fusion protein comprising an antigen binding domain and a cytokine trimer domain | |
WO2020246760A1 (ko) | 퇴행성관절염 예방 또는 치료용 항-oscar 항체 | |
WO2023158027A1 (en) | A fusion protein comprising an antigen binding domain and a cytokine trimer domain | |
WO2022010273A1 (ko) | 보체 경로 억제제를 포함하는 융합단백질 및 이의 용도 | |
WO2023132547A1 (ko) | 혈관신생 억제제가 결합된 항-c3b 항체 또는 항-c5 항체 및 이의 용도 | |
WO2019088658A1 (ko) | Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도 | |
WO2023055045A1 (ko) | 코일드 코일 융합 단백질 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22799183 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20237042487 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020237042487 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22799183 Country of ref document: EP Kind code of ref document: A1 |